SCHEMBL3065452

SCHEMBL3065452

CNc1ccc(Oc2ccc3c(c2)cc(C(=O)N2CCN(Cc4ccc5c(c4)OCO5)CC2)n3C)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 4/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 2/20 0.48
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48
MAPK10 P53779 1/20 0.48
TDP1 Q9NUW8 3/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 3/20 0.46
RXFP1 Q9HBX9 1/20 0.45
STAT3 P40763 2/20 0.45
FAAH O00519 1/20 0.45
KDM4E B2RXH2 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3064146 0.93 HPGD (0.51) HPGDUSP2LMNAALDH1A1SMN1; SMN2
SCHEMBL3054478 0.90 USP2 (0.48) HPGDUSP2LMNAALDH1A1SMN1; SMN2
SCHEMBL3057094 0.90 HPGD (0.53) HPGDUSP2LMNAALDH1A1SMN1; SMN2
SCHEMBL10180858 0.88 MEN1 (0.48) HPGDUSP2LMNAALDH1A1SMN1; SMN2
Bromide SCHEMBL3060756 0.88 MEN1 (0.47) HPGDUSP2LMNAALDH1A1SMN1; SMN2
SCHEMBL3064421 0.88 STAT3 (0.52) STAT3DRD3
SCHEMBL15295439 0.87 STAT3 (0.55) STAT3
SCHEMBL3056036 0.87 ALDH1A1 (0.53) HPGDUSP2LMNAALDH1A1SMN1; SMN2
Bromide SCHEMBL3067318 0.87 MEN1 (0.51) HPGDUSP2LMNAALDH1A1SMN1; SMN2
Bromide SCHEMBL3054787 0.87 STAT3 (0.54) STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 HPGD 263/4885USP2 4723/4885LMNA 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.